Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China.
Int Immunopharmacol. 2012 Feb;12(2):402-7. doi: 10.1016/j.intimp.2011.12.013. Epub 2012 Jan 2.
Although being promising tumor vaccine candidates in animal models, heat shock protein (HSP)-based tumor vaccines have not yet succeeded in the clinical trials, implying the necessity to be formulated with appropriate adjutants to enhance their immunogenicity. In this study, we investigated whether a B-class CpG ODN (BW006), a TLR9 agonist, could facilitate HSP65-Her2, a recombinant protein between mycobacterial HSP65 and Her2-derived peptide, to induce vigorous anti-tumor activity against Her2 positive tumors in mice both prophylactically and therapeutically. It was found that BW006 could enhance prophylactic and therapeutic effect of HSP65-Her2 with improved survival of the mice bearing Her2(+) B16 melanoma and HSP65-Her2 specific Th1 response.
尽管热休克蛋白（HSP）为基础的肿瘤疫苗在动物模型中具有很大的应用前景，但尚未在临床试验中取得成功，这意味着需要与适当的佐剂联合使用以增强其免疫原性。在这项研究中，我们研究了 B 类 CpG ODN（BW006），一种 TLR9 激动剂，是否可以促进 HSP65-Her2（一种分枝杆菌 HSP65 和 Her2 衍生肽之间的重组蛋白），从而在预防和治疗方面诱导针对 Her2 阳性肿瘤的强烈抗肿瘤活性。结果发现，BW006 可以增强 HSP65-Her2 的预防和治疗效果，提高荷 Her2（+）B16 黑色素瘤的小鼠的存活率，并增强 HSP65-Her2 特异性 Th1 反应。
